If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Dulaglutide is a GLP-1 RA indicated
as an adjunct to diet and exercise to improve glycemic control in adults with T2DM, and
to reduce the risk of MACE in adults with T2DM who have established CV disease or multiple CV risk factors.1
Enclosed Prescribing Information
TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
CV = cardiovascular
GLP-1 RA = glucagon-like peptide-1 receptor agonist
MACE = major adverse cardiovascular event
T2DM = type 2 diabetes mellitus
Date of Last Review: July 07, 2020
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST